Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | — | $1,986 | — | $4,288 |
| Operating expenses: | ||||
| Research and development | 38,636 | 20,141 | 72,445 | 35,706 |
| General and administrative | 12,146 | 8,598 | 21,823 | 16,756 |
| Net gain on lease termination | (3,433) | — | (3,433) | — |
| Total operating expenses | 47,349 | 28,739 | 90,835 | 52,462 |
| Loss from operations | (47,349) | (26,753) | (90,835) | (48,174) |
| Other income (expense): |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s G&A?
- Taysha Gene Therapies, Inc. (TSHA) reported G&A of $12.15M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s G&A changed year-over-year?
- Taysha Gene Therapies, Inc.'s G&A increased by 41.3% year-over-year, from $8.6M to $12.15M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s G&A?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s G&A has grown at a -4.9% compound annual growth rate (CAGR), from $41.32M to $33.87M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Taysha Gene Therapies, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude